person · Reporting owner

DArecca James

Disclosed activity across 4 companies

Tapewire entity: 26199
SEC CIK: 0001583903

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
HAEMONETICS CORPHAE · Entity 3953	EVP, Chief Financial Officer	May 15, 2026	May 19, 2026
Prestige Consumer Healthcare Inc.PBH · Entity 4350	Director	August 04, 2026	August 05, 2026
TherapeuticsMD, Inc.TXMD · Entity 7541	Chief Financial Officer	August 10, 2021	August 13, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HAEMONETICS CORP

Report date May 15, 2026 · Filed May 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	54,444	Last balance in matching sequence After 2026-05-15 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-05-15 · Tax withholding · Disposed 2,505 · Balance 25,132 F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2: This number includes unvested RSUs previously reported. Row 2 · 2026-05-15 · Grant · Acquired 29,312 · Balance 54,444 F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2: This number includes unvested RSUs previously reported.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported.

F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Prestige Consumer Healthcare Inc.

Report date August 04, 2026 · Filed August 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	9,572	Reported balance After 2026-08-04 transaction · row 1 1 source row Row 1 · 2026-08-04 · Grant · Acquired 2,981 · Balance 9,572 F1: The Reporting Person received 2,981 restricted stock units equal to $155,000 divided by the closing stock price of $52.00 on August 4, 2026, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person received 2,981 restricted stock units equal to $155,000 divided by the closing stock price of $52.00 on August 4, 2026, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.

TherapeuticsMD, Inc.

Report date August 10, 2021 · Filed August 13, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	123,830	Ending reported balance After 2021-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-08-10 · Exercise / conversion · Acquired 217,167 · Balance 217,167 F1: On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. Row 2 · 2021-08-12 · Sale · Disposed 93,337 · Balance 123,830 F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3: This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	434,333	Reported balance After 2021-08-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-08-10 · Exercise / conversion · Disposed 217,167 · Balance 434,333 F1: On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5: The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3: This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.

F5: The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Allergan plc

Report date May 08, 2020 · Filed May 11, 2020

Section 16 reporting ended · disclosed 2020-05-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-08 · Disposition to issuer · Disposed 3,511 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-05-08 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-05-08 · Disposition to issuer · Disposed 6,324 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $296.14 · Expires 2023-07-17	Direct	Reported balance After 2020-05-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-05-08 · Disposition to issuer · Disposed 1,169 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $224.00 · Expires 2023-07-17	Direct	Reported balance After 2020-05-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-05-08 · Disposition to issuer · Disposed 4,957 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-05-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-05-08 · Disposition to issuer · Disposed 3,534 · Balance 0 F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.

F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 04, 2026 Filed Aug 5, 2026 20:07 UTC	Prestige Consumer Healthcare Inc. PBH · Entity 4350	GrantCommon Stock, par value $0.01 per share	2,981	$0.00	$0.00	Disclosure SEC source: 0001104659-26-091082 · tm2622318-3_4seq1.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,572 F1 · shares: The Reporting Person received 2,981 restricted stock units equal to $155,000 divided by the closing stock price of $52.00 on August 4, 2026, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control. Read SEC document
May 15, 2026 Filed May 19, 2026 21:34 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantCommon Stock	29,312	Not disclosed	Not disclosed	Disclosure SEC source: 0000313143-26-000046 · form4.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,444 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 15, 2026 Filed May 19, 2026 21:34 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	2,505	$56.29	$141,006.45	Disclosure SEC source: 0000313143-26-000046 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,132 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 01, 2026 Filed May 5, 2026 20:24 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	655	$59.26	$38,815.30	Disclosure SEC source: 0000313143-26-000026 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,637 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
August 05, 2025 Filed Aug 6, 2025 20:02 UTC	Prestige Consumer Healthcare Inc. PBH · Entity 4350	GrantCommon Stock, par value $0.01 per share	2,094	$0.00	$0.00	Disclosure SEC source: 0001104659-25-074702 · tm2522759-3_4seq1.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,591 F1 · shares: The Reporting Person received 2,094 restricted stock units equal to $155,000 divided by the closing stock price of $674.04 on August 5, 2025, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control. Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:35 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	5,864	$69.38	$406,844.32	Disclosure SEC source: 0001127602-25-016517 · form4.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,292 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:35 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantCommon Stock	12,221	$0.00	$0.00	Disclosure SEC source: 0001127602-25-016517 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,156 F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document
May 16, 2025 Filed May 19, 2025 21:15 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	1,246	$70.31	$87,606.26	Disclosure SEC source: 0001127602-25-014944 · form4.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,824 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 16, 2025 Filed May 20, 2025 21:14 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantNon-qualified Stock Option (Right to Buy) · Derivative	15,396	$0.00 Strike: $70.31	$0.00	Disclosure SEC source: 0001127602-25-015054 · form4.xml · derivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,396 Underlying: Common Stock · 15,396 shares Expires 2032-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document
May 16, 2025 Filed May 20, 2025 21:14 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantCommon Stock	7,111	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-015054 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,935 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 15, 2025 Filed May 19, 2025 21:15 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	622	$69.38	$43,154.36	Disclosure SEC source: 0001127602-25-014944 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,070 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 02, 2025 Filed May 5, 2025 20:16 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	654	$63.85	$41,757.90	Disclosure SEC source: 0001127602-25-013343 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,692 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
August 06, 2024 Filed Aug 7, 2024 20:04 UTC	Prestige Consumer Healthcare Inc. PBH · Entity 4350	GrantCommon Stock, par value $0.01 per share	2,202	$0.00	$0.00	Disclosure SEC source: 0001104659-24-086748 · tm2421115-5_4seq1.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,497 F1 · shares: The Reporting Person received 2,202 restricted stock units equal to $150,000 divided by the closing stock price of $68.13 on August 6, 2024, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control. Read SEC document
May 17, 2024 Filed May 21, 2024 21:41 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantNon-qualified Stock Option (Right to Buy) · Derivative	9,756	$0.00 Strike: $95.73	$0.00	Disclosure SEC source: 0001127602-24-016162 · form4.xml · derivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,756 Underlying: Common Stock · 9,756 shares Expires 2031-05-17 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document
May 17, 2024 Filed May 21, 2024 21:41 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantCommon Stock	4,439	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-016162 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,346 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 16, 2024 Filed May 17, 2024 20:52 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	351	$94.80	$33,274.80	Disclosure SEC source: 0001127602-24-015864 · form4.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,907 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 15, 2024 Filed May 17, 2024 20:52 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	412	$96.49	$39,753.88	Disclosure SEC source: 0001127602-24-015864 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,258 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 02, 2024 Filed May 6, 2024 20:19 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	432	$93.33	$40,318.56	Disclosure SEC source: 0001127602-24-014274 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,670 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
August 01, 2023 Filed Aug 3, 2023 18:01 UTC	Prestige Consumer Healthcare Inc. PBH · Entity 4350	GrantCommon Stock, par value $0.01 per share	2,295	$0.00	$0.00	Disclosure SEC source: 0001104659-23-087189 · tm2322776-3_4seq1.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,295 F1 · shares: The Reporting Person received 2,295 restricted stock units equal to $150,000 divided by the closing stock price of $65.37 on August 1, 2023, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control. Read SEC document
May 16, 2023 Filed May 17, 2023 20:26 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	349	$89.21	$31,134.29	Disclosure SEC source: 0001127602-23-015929 · form4.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,102 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 15, 2023 Filed May 17, 2023 20:26 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantNon-qualified Stock Option (Right to Buy) · Derivative	9,502	$0.00 Strike: $89.16	$0.00	Disclosure SEC source: 0001127602-23-015929 · form4.xml · derivative · entry 3 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,502 Underlying: Common Stock · 9,502 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document
May 15, 2023 Filed May 17, 2023 20:26 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantCommon Stock	4,205	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-015929 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,451 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 02, 2023 Filed May 4, 2023 20:27 UTC	HAEMONETICS CORP HAE · Entity 3953	Tax withholdingCommon Stock	430	$81.66	$35,113.80	Disclosure SEC source: 0001127602-23-014489 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,246 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 16, 2022 Filed May 18, 2022 20:34 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantNon-qualified Stock Option (Right to Buy) · Derivative	11,163	$0.00 Strike: $57.60	$0.00	Disclosure SEC source: 0001127602-22-014966 · form4.xml · derivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,163 Underlying: Common Stock · 11,163 shares Expires 2029-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document
May 16, 2022 Filed May 18, 2022 20:34 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantCommon Stock	4,774	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-014966 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,676 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document
May 02, 2022 Filed May 4, 2022 20:41 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantNon-qualified Stock Option (Right to Buy) · Derivative	13,828	$0.00 Strike: $50.83	$0.00	Disclosure SEC source: 0001127602-22-013206 · form4.xml · derivative · entry 2 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,828 Underlying: Common Stock · 13,828 shares Expires 2029-05-02 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document
May 02, 2022 Filed May 4, 2022 20:41 UTC	HAEMONETICS CORP HAE · Entity 3953	GrantCommon Stock	5,902	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-013206 · form4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,902 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document
August 12, 2021 Filed Aug 13, 2021 01:33 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	SaleCommon Stock	93,337	$0.87	$81,203.19	Disclosure SEC source: 0001387131-21-008437 · ownership.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,830 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. F3 · price: This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
August 10, 2021 Filed Aug 13, 2021 01:33 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	Exercise / conversionRestricted Stock Units · Derivative	217,167	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001387131-21-008437 · ownership.xml · derivative · entry 3 DArecca James · CIK 0001583903 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,333 Underlying: Common Stock · 217,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F4 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5 · derivative.exercise_date: The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023. F5 · derivative.expiration_date: The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023. F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F4 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document
August 10, 2021 Filed Aug 13, 2021 01:33 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	Exercise / conversionCommon Stock	217,167	Not disclosed	Not disclosed	Disclosure SEC source: 0001387131-21-008437 · ownership.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. Read SEC document
July 01, 2021 Filed Jul 2, 2021 21:45 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	GrantRestricted Stock Units · Derivative	173,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001387131-21-007115 · ownership.xml · derivative · entry 2 DArecca James · CIK 0001583903 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,333 Underlying: Common Stock · 173,333 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024. Read SEC document
July 01, 2021 Filed Jul 2, 2021 21:45 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	GrantPerformance Stock Units · Derivative	346,667	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001387131-21-007115 · ownership.xml · derivative · entry 1 DArecca James · CIK 0001583903 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,667 Underlying: Common Stock · 346,667 shares Expires not disclosed F1 · shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · balance_after: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 18, 2020 Filed Jun 19, 2020 21:07 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	GrantRestricted Stock Units · Derivative	651,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001387131-20-005814 · ownership.xml · derivative · entry 2 DArecca James · CIK 0001583903 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,500 Underlying: Common Stock · 651,500 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023. Read SEC document
June 18, 2020 Filed Jun 19, 2020 21:07 UTC	TherapeuticsMD, Inc. TXMD · Entity 7541	GrantPerformance Stock Units · Derivative	151,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001387131-20-005814 · ownership.xml · derivative · entry 1 DArecca James · CIK 0001583903 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,500 Underlying: Common Stock · 151,500 shares Expires not disclosed F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 18, 2020 Filed Aug 8, 2020 01:16 UTC Amendment	TherapeuticsMD, Inc. TXMD · Entity 7541	GrantRestricted Stock Units · Derivative	651,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001387131-20-007227 · darecca-form4a_061820.xml · derivative · entry 2 DArecca James · CIK 0001583903 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,500 Underlying: Common Stock · 651,500 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023. Read SEC document
June 18, 2020 Filed Aug 8, 2020 01:16 UTC Amendment	TherapeuticsMD, Inc. TXMD · Entity 7541	GrantPerformance Stock Units · Derivative	151,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001387131-20-007227 · darecca-form4a_061820.xml · derivative · entry 1 DArecca James · CIK 0001583903 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,500 Underlying: Common Stock · 151,500 shares Expires not disclosed F1 · shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · balance_after: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document
May 08, 2020 Filed May 11, 2020 21:50 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerPerformance Stock Units · Derivative	3,534	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-012758 · doc4.xml · derivative · entry 5 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,534 shares Expires not disclosed F5 · derivative.exercise_price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F5 · price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F5 · derivative.exercise_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F5 · derivative.expiration_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). Read SEC document
May 08, 2020 Filed May 11, 2020 21:50 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerStock Options · Derivative	4,957	$0.00 Strike: $224.00	$0.00	Disclosure SEC source: 0000899243-20-012758 · doc4.xml · derivative · entry 4 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,957 shares Expires 2023-07-17 F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. Read SEC document
May 08, 2020 Filed May 11, 2020 21:50 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerStock Options · Derivative	1,169	$0.00 Strike: $296.14	$0.00	Disclosure SEC source: 0000899243-20-012758 · doc4.xml · derivative · entry 3 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,169 shares Expires 2023-07-17 F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. Read SEC document
May 08, 2020 Filed May 11, 2020 21:50 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerRestricted Stock Units	6,324	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012758 · doc4.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · balance_after: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement. Read SEC document
May 08, 2020 Filed May 11, 2020 21:50 UTC	Allergan plc AGN · Entity 149298	Disposition to issuerOrdinary Shares, par value $0.0001	3,511	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012758 · doc4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. Read SEC document
March 06, 2020 Filed Mar 10, 2020 14:10 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	718	$191.95	$137,820.10	Disclosure SEC source: 0000899243-20-007719 · doc4.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,834 F1 · balance_after: Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. Read SEC document
March 02, 2020 Filed Mar 4, 2020 14:22 UTC	Allergan plc AGN · Entity 149298	GrantOrdinary Shares, par value $0.0001	3,611	$193.84	$699,956.24	Disclosure SEC source: 0001179110-20-003042 · edgar.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,552 F1 · balance_after: Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. Read SEC document
December 31, 2019 Filed Jan 2, 2020 17:52 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	92	$191.17	$17,587.64	Disclosure SEC source: 0001179110-20-000043 · edgar.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,941 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
March 08, 2019 Filed Mar 11, 2019 17:49 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	113	$145.06	$16,391.78	Disclosure SEC source: 0001179110-19-003702 · edgar.xml · nonDerivative · entry 2 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,033 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
March 07, 2019 Filed Mar 11, 2019 17:49 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	359	$143.00	$51,337.00	Disclosure SEC source: 0001179110-19-003702 · edgar.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,146 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
March 06, 2019 Filed Mar 8, 2019 15:27 UTC	Allergan plc AGN · Entity 149298	GrantOrdinary Shares, par value $0.0001	2,036	$137.51	$279,970.36	Disclosure SEC source: 0001179110-19-003597 · edgar.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,505 F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 6, 2020, twenty-five percent (25%) on March 6, 2021, twenty-five percent (25%) on March 6, 2022 and twenty-five percent (25%) on March 6, 2023. F2 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
March 04, 2019 Filed Mar 6, 2019 15:49 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	114	$139.12	$15,859.68	Disclosure SEC source: 0001179110-19-003412 · edgar.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,469 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
December 31, 2018 Filed Jan 3, 2019 15:50 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	147	$133.66	$19,648.02	Disclosure SEC source: 0001179110-19-000195 · edgar.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · SVP Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,453 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document
March 08, 2018 Filed Mar 9, 2018 16:34 UTC	Allergan plc AGN · Entity 149298	Tax withholdingOrdinary Shares, par value $0.0001	79	$153.50	$12,126.50	Disclosure SEC source: 0001179110-18-003970 · edgar.xml · nonDerivative · entry 1 DArecca James · CIK 0001583903 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.